Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02511106 · ClinicalTrials.gov registry record · Phase 3

AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.

A Phase 3 study of Stage IB-IIIA Non-small Cell Lung Carcinoma, sponsored by AstraZeneca.

Active
Registry status
Phase 3
Development phase
682
Enrollment target
20
Study locations

NCT02511106: Active Phase 3 study of Stage IB-IIIA Non-small Cell Lung Carcinoma, sponsored by AstraZeneca.

NCT02511106 is a Phase 3 study of Stage IB-IIIA Non-small Cell Lung Carcinoma that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 682 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (12% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02511106, a Phase 3 study of Stage IB-IIIA Non-small Cell Lung Carcinoma, is active but no longer recruiting, sponsored by AstraZeneca.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
682 participants
Enrollment target
20
Study locations

Study Summary

To assess the efficacy and safety of AZD9291 versus Placebo, in patients with Epidermal Growth Factor Receptor Mutation Positive stage IB-IIIA non-small cell lung carcinoma, following complete tumour resection with or without adjuvant chemotherapy

Primary Outcome

Defined as the time from the date of randomization until the date of disease recurrence or death (by any cause in the absence of recurrence).

Conditions Studied

Stage IB-IIIA Non-small Cell Lung Carcinoma

Interventions

  • DRUG AZD9291 80 mg/40 mg
  • DRUG Placebo AZD9291 80 mg/40 mg
  • DRUG Open-label AZD9291 80 mg/40 mg

Study Locations (20)

California

  • Research Site - Los Angeles
  • Research Site - Santa Monica
  • Research Site - Santa Rosa
  • Research Site - Torrance

Florida

  • Research Site - Fort Myers
  • Research Site - Pembroke Pines
  • Research Site - St. Petersburg

Connecticut

  • Research Site - New Haven
  • Research Site - Norwalk

Illinois

  • Research Site - Chicago
  • Research Site - Elk Grove Village

New Jersey

  • Research Site - Brick
  • Research Site - Florham Park

Colorado

  • Research Site - Grand Junction

Georgia

  • Research Site - Athens

Hawaii

  • Research Site - Honolulu

Trial Details

FieldValue
Enrollment Target 682 participants
Start Date 2015-10-21
Est. Completion 2029-01-31
Phase Phase 3
AstraZeneca

1,285 total trials

What the registry record for NCT02511106 still lists

NCT02511106 is an interventional study that assigns participants to a tested intervention. The registered 682 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (12% lower).

The record links to 1 condition, with Stage IB-IIIA Non-small Cell Lung Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which AZD9291 80 mg/40 mg is the first listed.

NCT02511106 names 20 study sites across 12 states, led by California, Florida, Connecticut.

Frequently Asked Questions

What is clinical trial NCT02511106 about?

NCT02511106 is a clinical study titled "AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.". To assess the efficacy and safety of AZD9291 versus Placebo, in patients with Epidermal Growth Factor Receptor Mutation Positive stage IB-IIIA non-small cell lung carcinoma, following complete tumour resection with or without adjuvant chemotherapy

What is the current status of trial NCT02511106?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 682 participants. The study started on 2015-10-21. Estimated completion is 2029-01-31.

What conditions does trial NCT02511106 study?

This clinical trial studies the following conditions: Stage IB-IIIA Non-small Cell Lung Carcinoma.

What interventions are being tested in trial NCT02511106?

The interventions under investigation include: AZD9291 80 mg/40 mg (DRUG), Placebo AZD9291 80 mg/40 mg (DRUG), Open-label AZD9291 80 mg/40 mg (DRUG).

Who is sponsoring clinical trial NCT02511106?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02511106 being conducted?

This trial has 20 study locations across California, Colorado, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

How this trial's enrollment target compares

Where NCT02511106's enrollment target sits among peer trials

682 529th of 2000 higher than 1,472 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05382559 · 681 participants · Phase 1

    A Study of ASP3082 in Adults With Advanced Solid Tumors

  • NCT06795087 · 684 participants

    Discharge Medication Use Post-Operatively in GU Cancer Patients

  • NCT03501706 · 680 participants · NA

    An Assessment of Cognitive Improvement Training Among Mid-life Individuals

  • NCT05626452 · 680 participants · NA

    PrEP Optimization Among Women to Enhance Retention and Uptake

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT02511106, the US trial registry maintained by the National Library of Medicine. NCT02511106 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.